Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Sputnik-V"

47 News Found

RDIF offers vaccine for adolescents aged 12-17 in India
News | December 07, 2021

RDIF offers vaccine for adolescents aged 12-17 in India

Sputnik M is a new member of the Sputnik vaccines family


UAE authorises Sputnik Light vaccine as universal booster
News | November 30, 2021

UAE authorises Sputnik Light vaccine as universal booster

Booster dose is available to all residents aged 18+ and can be applied six months after the second dose of any other vaccine administered in UAE


Sputnik Light in India by December: RDIF
News | November 25, 2021

Sputnik Light in India by December: RDIF

One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster


Lancet endorses Sputnik Light for safety and immune response
News | November 03, 2021

Lancet endorses Sputnik Light for safety and immune response

Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries


We are marketing all our products globally: Samit Jain, MD, PLUSS
interviews | October 25, 2021

We are marketing all our products globally: Samit Jain, MD, PLUSS

Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business


Sputnik Light has 70 % efficacy against infection with Delta: Gamaleya analysis
Biotech | October 14, 2021

Sputnik Light has 70 % efficacy against infection with Delta: Gamaleya analysis

Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations


Promising prospects for Indian pharma: CLSA
News | September 17, 2021

Promising prospects for Indian pharma: CLSA

CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report


DGCI gives a go-ahead for Phase III Sputnik Light trials
News | September 16, 2021

DGCI gives a go-ahead for Phase III Sputnik Light trials

The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines


Reliance Life Science gets go-ahead for Phase I clinical trial for Covid-19 vaccine
Drug Approval | September 04, 2021

Reliance Life Science gets go-ahead for Phase I clinical trial for Covid-19 vaccine

The trial will be conducted across eight sites in Maharashtra


SEC recommends Phase I clinical trials for Reliance’s Covid-19 vaccine candidate
News | August 27, 2021

SEC recommends Phase I clinical trials for Reliance’s Covid-19 vaccine candidate

The company has to approach the DCGI for approval to commence the trials